• Glycogen Colorimetric Assay Kit II: Applied Workflows & Insi

  2026-07-03

  The Glycogen Colorimetric Assay Kit II delivers high-throughput, interference-resistant glycogen quantification, empowering metabolic research even in challenging sample matrices. Leverage its robust workflow for studies on exercise adaptation, disease models, and glycogen metabolism, with practical troubleshooting and protocol optimization drawn from recent experimental advances.

• L-Phenylephrine: Advanced Insights Into α1A Receptor Agonism

  2026-07-02

  Explore L-Phenylephrine as a selective adrenergic α1A receptor agonist, uncovering advanced mechanisms, protocol guidance, and sex-specific cardiovascular research insights. This in-depth analysis offers practical recommendations and bridges experimental findings to assay design.

• ESCO2 as a Pan-Cancer Biomarker: Insights from Multi-Omic An

  2026-07-02

  This study provides the first comprehensive pan-cancer analysis of ESCO2, revealing its consistent upregulation in most tumor types and its association with poor prognosis and cell proliferation. The research integrates large-scale database mining with in vitro validation, positioning ESCO2 as a promising biomarker and potential therapeutic target in oncology.

• Dacomitinib (PF-00299804): Unraveling Irreversible Pan-HER I

  2026-07-01

  Explore the advanced mechanisms of Dacomitinib (PF-00299804), a potent pan-HER inhibitor, and its role in apoptosis induction, cell cycle arrest, and resistance mechanisms in cancer research. This article uniquely integrates emerging insights from mitochondrial ferroptosis regulation to guide optimal experimental design.

• BMS-777607: Advanced c-Met Inhibitor for Platelet and Cancer

  2026-07-01

  BMS-777607 is redefining the MET signaling pathway inhibition, bridging breakthroughs in cancer metastasis modeling with cost-effective, hiPSC-based platelet production workflows. This article details actionable protocol enhancements, troubleshooting insights, and practical cross-domain use-cases that maximize reproducibility and translational value.

• Chlorin e6 (Ce6): Unlocking Pyroptosis and Immune Activation

  2026-06-30

  Explore how the Ce6 photosensitizer revolutionizes anticancer photodynamic therapy by inducing pyroptosis and robust immune responses. This article uncovers the practical significance of these findings and offers advanced guidance for research workflows.

• CX-4945 (Silmitasertib): CK2 Inhibition and Cancer Stemness

  2026-06-30

  Explore the advanced mechanisms and translational impact of CX-4945 (Silmitasertib) as a selective CK2 inhibitor, focusing on its unique role in targeting cancer stemness and therapy resistance. This article offers deep scientific insight and practical guidance for cancer research applications.

• Influenza Hemagglutinin (HA) Peptide: Precision in Protein T

  2026-06-29

  This article provides evidence-based guidance for deploying Influenza Hemagglutinin (HA) Peptide (SKU A6004) in workflows requiring reliable detection, purification, and elution of HA-tagged proteins. Drawing from recent literature and validated product specifications, we address common laboratory challenges and illustrate how A6004 ensures reproducibility and workflow efficiency.

• LY2228820: Applied Workflows for p38 MAP Kinase Inhibitor Re

  2026-06-29

  LY2228820 enables precision targeting of p38 MAPK signaling with dual-action inhibition and dephosphorylation, offering unique assay control for anti-inflammatory and cancer studies. Leveraging new mechanistic insights, this guide details best-practice protocols, troubleshooting, and workflow optimizations that set LY2228820 apart for advanced research applications.

• NADH/NAD+ Redox Imbalance in Diabetic Kidney Disease: Mechan

  2026-06-28

  The referenced review by Liang-Jun Yan systematically analyzes how NADH/NAD⁺ redox imbalance contributes to diabetic kidney disease (DKD), emphasizing mitochondrial dysfunction as a central pathogenic mechanism. The paper integrates metabolic pathway analysis with potential intervention strategies, highlighting the need for targeted approaches to restore redox balance in DKD.

• NLRP10’s Role in Keratinocyte Survival and Skin Barrier Func

  2026-06-27

  This study establishes NLRP10 as a crucial regulator of epidermal homeostasis, demonstrating its necessity for keratinocyte survival and P63-dependent differentiation. The findings clarify NLRP10’s mechanistic functions in maintaining barrier integrity in atopic dermatitis, positioning it as a promising target for therapeutic intervention.

• D-Luciferin Sodium Salt: Optimizing Firefly Luciferase Workf

  2026-06-26

  D-Luciferin sodium salt, supplied by APExBIO, empowers high-sensitivity, ATP-dependent bioluminescence assays for real-time analysis of cell viability, gene expression, and metabolic dynamics. Recent advances in CAR macrophage immunotherapy demonstrate the critical importance of luciferase-based imaging for both mechanistic insight and translational oncology workflows.

• Trolox in Translational Research: Redox Strategies for Antio

  2026-06-26

  Explore how Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) catalyzes advances in oxidative injury research and high-throughput antioxidant screening. This article bridges mechanistic redox biology, experimental assay design, and translational imperatives—highlighting competitive insights from immobilized microalgae studies and strategic deployment of APExBIO Trolox as the benchmark antioxidant control.

• TPCA-1: Decoding Selective IKK-2 Inhibition in Inflammatory

  2026-06-25

  Explore how TPCA-1, a potent IKK-2 inhibitor, enables unprecedented precision in dissecting NF-κB pathway inhibition and cell death mechanisms. This article delivers unique insights on RIPK1 regulation and practical assay strategies for inflammation and rheumatoid arthritis research.

• 25-Hydroxycholesterol Drives TAM Immunometabolic Reprogrammi

  2026-06-25

  Xiao et al. reveal that lysosomal 25-hydroxycholesterol orchestrates tumor-associated macrophage (TAM) immunosuppression via AMPKα-STAT6 signaling and metabolic reprogramming. Targeting this axis enhances anti-tumor immunity and synergizes with immune checkpoint blockade, highlighting a novel intervention point for cancer metabolism research.

442 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page